Benzinga | Jul 12, 2021 08:08AM EDT

DSS's Impact BioMedical Announces US Patent For Its Proprietary Equivir Compound

Impact BioMedical Inc., a wholly owned subsidiary of Document Security Systems Inc. (NYSE:DSS), today announced it was issued a patent (Patent # 11,033,528) on June 15, 2021, from the U.S. Patent and Trademark Office for its proprietary compound Equivir. This is a follow-up to the release on April 6, 2021, for the allowance of this patent. The compound has displayed positive pre-clinical results that reduce the risk and/or severity attributable to viral infections, specifically Ebola and Rhinovirus.